GLOW Blend (GHK-Cu + BPC-157 + TB-500): Complete Research Guide — Three Non-Overlapping Mechanisms, 1,600+ Combined Publications & White-Label Pricing (2026)
- The GLOW Blend is a fixed-dose co-lyophilized research formulation containing GHK-Cu (~45mg), BPC-157 (10mg), and TB-500 (10mg) — three compounds that address tissue repair through entirely non-overlapping molecular mechanisms: gene expression reprogramming (GHK-Cu), VEGFR2/NO vascularization (BPC-157), and G-actin-mediated cell migration (TB-500).
- Combined published literature: 1,600+ PubMed publications across all three component compounds (GHK-Cu: 300+, BPC-157: 800+, TB-500: 400+) — the largest combined evidence base of any three-compound research blend in the YPB healing category.
- No published randomized controlled trial exists for the GLOW Blend co-formulation as a single intervention. Combination rationale derives from documented mechanistic non-overlap of all three components and from Wolverine Blend (BPC-157 + TB-500) co-administration preclinical literature extended by GHK-Cu’s 4,000+ gene modulation profile.
- The GLOW Blend extends the Wolverine Blend (BPC-157 + TB-500) model by adding GHK-Cu’s gene expression layer — addressing what neither BPC-157 nor TB-500 alone can provide: epigenetic-level resetting of gene expression toward patterns characteristic of younger tissue.
- Research-grade GLOW Blend is available as YPB.218 (Research Use Only) with tri-compound batch-specific COAs through the YPB catalog.
- $83.04 gross margin per unit at Premier tier (50%); the highest-margin three-compound blend in the YPB healing category and the natural upgrade path from the Wolverine Blend. Updated April 2026.
What Is the GLOW Blend and Why Combine Three Compounds?
1,600+ Combined Publications
Gene Expression + Vascularization + Cell Migration
The GLOW Blend (YPB.218) is a fixed-dose co-lyophilized research formulation combining GHK-Cu (glycyl-L-histidyl-L-lysine copper(II), ~45mg), BPC-157 (Body Protection Compound-157, 10mg), and TB-500 (Thymosin Beta-4, 10mg) in a single vial. Updated April 2026. The combination is built on a three-tier mechanistic rationale: each compound addresses a distinct cellular requirement of tissue repair and regeneration research, and no two of the three compounds share a receptor, a signaling pathway, or a downstream effector molecule. Where the Wolverine Blend (BPC-157 + TB-500) provides vascularization and cell migration, the GLOW Blend extends the model by adding GHK-Cu’s gene expression reprogramming layer — addressing the epigenetic and transcriptional environment in which tissue repair operates.
It is important to state clearly for research accuracy: no published randomized controlled trial exists for the co-formulated GLOW Blend as a single intervention. All three components have been independently researched and published extensively — GHK-Cu with 300+ publications, BPC-157 with 800+, TB-500 with 400+ — and the combination rationale derives from the mechanistic non-overlap documented in the independent compound literatures and from preclinical co-administration models. Researchers designing protocols should document this distinction.
Component Compound Profiles at a Glance
| Parameter | GHK-Cu (~45mg) | BPC-157 (10mg) | TB-500 (10mg) |
|---|---|---|---|
| CAS Number | 49557-75-7 | 137525-51-0 | 77591-33-4 |
| Molecular Weight | 403.93 Da | 1,419.5 Da | 4,963 Da |
| Amino Acids | 3 (tripeptide-copper complex) | 15 (pentadecapeptide) | 43 (full-length Tβ4) |
| Primary Mechanism | Gene expression reprogramming (4,000+ genes modulated at nanomolar concentrations); copper metalloenzyme activation; collagen synthesis | VEGFR2 upregulation + nitric oxide pathway activation → local/regional angiogenesis | G-actin sequestration (LKKTETQ domain) → systemic cell migration enhancement |
| Reach | Systemic gene expression; plasma-level endogenous molecule | Local/regional (target tissue) | Systemic (concentrates at injury sites) |
| Half-Life | Naturally circulating; tripeptide with copper stabilization | ~4 hours (preclinical) | ~3–5 days (preclinical) |
| Key Research Area | Collagen/ECM remodeling, wound healing, dermal, neuroprotection, gene expression aging reversal models | GI tract, tendon, bone, musculoskeletal, vascular | Wound healing, cardiac, ophthalmic, musculoskeletal |
| Clinical Pipeline | Cosmeceutical INCI approved; dermal data; no compound approval | Phase 2 (GI indications) | Phase 3 (RGN-259, NK); Orphan compound 2013 |
| PubMed Publications | 300+ | 800+ | 400+ |
| WADA Status | Not listed (copper tripeptide) | Prohibited (S2) | Prohibited (S2) |
| Storage | Lyophilized: −20°C. Reconstituted: 2–8°C, 14 days | Lyophilized: −20°C. Reconstituted: 2–8°C, 14 days | Lyophilized: −20°C. Reconstituted: 2–8°C, 14 days |
Why Do Three Non-Overlapping Mechanisms Make a Stronger Research Case Than Two?
The Wolverine Blend research guide establishes the two-mechanism rationale: BPC-157 (VEGFR2/NO, local vascularization) and TB-500 (G-actin/LKKTETQ, systemic cell migration) address different cellular bottlenecks in tissue repair. The GLOW Blend adds a third dimension that neither BPC-157 nor TB-500 can access.
GHK-Cu: The Gene Expression Layer
GHK-Cu’s distinguishing property in the context of this combination is its gene expression reach. Genome-wide expression profiling by Pickart et al. (2018) demonstrated that GHK-Cu modulates 4,000+ human genes at nanomolar concentrations, with a particular pattern of resetting gene expression toward profiles characteristic of younger, healthier tissue (Pickart et al., Int J Mol Sci, 2018 — PMID: 30011848). This includes upregulation of genes encoding collagen types I, III, and IV; fibronectin; proteoglycan; and metalloproteinases involved in ECM remodeling — creating the transcriptional environment that BPC-157’s vascular network and TB-500’s recruited cells need to operate within.
Neither BPC-157 nor TB-500 operates at the gene expression level in this way. BPC-157 activates VEGFR2 receptor signaling; TB-500 sequesters G-actin. Neither alters the epigenetic and transcriptional environment of the target tissue directly. GHK-Cu’s 4,000+ gene modulation creates the cellular context — the ECM composition, the inflammatory gene profile, the collagen synthesis capacity — within which the vascular (BPC-157) and migratory (TB-500) activities operate.
BPC-157: The Vascular Infrastructure Layer
As established in the BPC-157 Research Guide, VEGFR2 upregulation and NO pathway activation produce angiogenesis — new blood vessel formation — at the target tissue site. This local vascular infrastructure is a prerequisite for the repair process that TB-500’s recruited cells will execute. BPC-157 ensures adequate oxygen and nutrient delivery to the repair zone created by the combined action of all three compounds.
TB-500: The Cell Mobilization Layer
As established in the TB-500 Research Guide, LKKTETQ-domain G-actin sequestration mobilizes repair cells systemically, directing them toward injury sites throughout the body. In the context of the GLOW Blend, these cells arrive at a tissue site where GHK-Cu has established a pro-repair gene expression environment and BPC-157 has developed the vascular supply to sustain repair activity.
What Published Research Supports the Component Compounds?
Since no published RCT exists for the co-formulated GLOW Blend, this section summarizes the independent evidence for each component. Full citation detail is in the individual compound research guides.
GHK-Cu Component: Key Published Data
GHK-Cu is naturally present in human plasma at ~200 ng/mL at age 20, declining approximately 60% by age 60 — a correlation with the age-related decline in tissue repair capacity that has driven substantial research interest. Published data demonstrates GHK-Cu’s role in stimulating collagen synthesis, promoting wound contraction, activating metalloproteinases for ECM remodeling, producing antioxidant and anti-inflammatory effects, and in the landmark 2018 genome-wide study, modulating over 4,000 genes associated with tissue regeneration, oxidative stress, and inflammation at nanomolar concentrations (Pickart et al., PMID: 30011848). The copper component activates lysyl oxidase for collagen cross-linking and superoxide dismutase for antioxidant defense. Full evidence reviewed in the GHK-Cu Research Guide.
BPC-157 Component: Key Published Data
BPC-157 has the most extensive preclinical literature of any compound in the YPB healing category (800+ publications). The 2019 Gwyer et al. systematic review in Wound Repair and Regeneration documented consistent acceleration of healing across multiple tissue types, attributing the primary mechanism to VEGFR2-mediated angiogenesis and NO pathway upregulation (PMID: 31309676). A Phase 2 IBD trial (NCT03000296) is ongoing in humans. Full evidence reviewed in the BPC-157 Research Guide.
TB-500 Component: Key Published Data
TB-500 has the most advanced clinical program of any healing compound in the YPB catalog: Phase 3 RGN-259 data (60% corneal healing at 4 weeks vs. 12.5% placebo), FDA Orphan compound Designation (2013), and 1,700+ subjects across all trials with no serious adverse events. Philp et al. (2004, PMID: 15100427) documented the breadth of TB-500’s wound healing activity across dermal, cardiac, ophthalmic, and musculoskeletal models. Full evidence in the TB-500 Research Guide.
What Does the Human Research Data Show So Far?
As with the Wolverine Blend, human data for the co-formulated GLOW Blend does not exist in published form. The table below covers the human evidence for each component compound independently. Researchers designing human-context research protocols should treat this data as compound-specific rather than blend-specific.
Human Safety Summary (Component Compounds)
| Compound | Study Type | Route | N | Adverse Events | Year |
|---|---|---|---|---|---|
| GHK-Cu | Dermal cosmeceutical studies; INCI-approved ingredient | Topical | Multiple cosmeceutical trials | Well tolerated in all published topical studies. No systemic adverse events in topical cosmeceutical literature. Injectable data limited. | Various |
| BPC-157 | Phase 2 IBD trial (NCT03000296, oral PL-10) | Oral capsule | Trial ongoing; preliminary data | No serious compound-related adverse events in preliminary disclosures; well tolerated at studied doses. | 2017–ongoing |
| TB-500 | SEER-1 Phase 3 RCT (RGN-259, ophthalmic) | Topical ophthalmic | 18 | No serious compound-related adverse events. Well tolerated at all study doses. | 2023 |
| GLOW Blend (all three) | No published co-formulated combination RCT as of April 2026 | N/A | N/A | No published combination data. Component-level safety data available individually above. | N/A |
GLOW Blend vs. Wolverine Blend vs. Standalone Compounds
The most important research positioning question for the GLOW Blend is how it relates to the Wolverine Blend and to the standalone compounds. The answer is purely about research protocol requirements and the number of mechanisms the investigator needs to activate simultaneously.
| Parameter | GLOW Blend | Wolverine Blend (BPC-157 + TB-500) | GHK-Cu Standalone | BPC-157 Standalone |
|---|---|---|---|---|
| Components | GHK-Cu + BPC-157 + TB-500 | BPC-157 + TB-500 | GHK-Cu only | BPC-157 only |
| Mechanisms Active | 3: Gene expression + VEGFR2/NO + G-actin | 2: VEGFR2/NO + G-actin | 1: Gene expression / ECM remodeling | 1: VEGFR2/NO angiogenesis |
| Mechanism Overlap | None (all three fully non-overlapping) | None (both non-overlapping) | N/A | N/A |
| Gene Expression Scale | Yes — 4,000+ genes (GHK-Cu) | No | Yes | No |
| Angiogenesis/Vascular | Yes (BPC-157) | Yes (BPC-157) | Partial (GHK-Cu promotes angiogenesis via different mechanism) | Yes |
| Systemic Cell Migration | Yes (TB-500) | Yes (TB-500) | No | No |
| Published Combo RCT | None for GLOW Blend specifically | None for Wolverine Blend specifically | N/A (standalone compound) | Phase 2 GI trial ongoing |
| Combined Evidence Base | 1,600+ publications (all three) | 1,200+ publications (two compounds) | 300+ standalone | 800+ standalone |
| YPB MSRP | $165.00 | $100–$180 (5mg/10mg configs) | $80–$130 (50mg/100mg) | $50–$100 (5mg/10mg) |
The upgrade path from Wolverine to GLOW is the most intuitive upsell in the YPB healing catalog: researchers already using BPC-157 + TB-500 extend their protocol to include GHK-Cu’s gene expression layer by simply switching to the GLOW Blend. White-label brands should position this as a natural protocol evolution rather than a product replacement, since researchers may continue using all three formulations for different experimental arms.
What Should Researchers Know About GLOW Blend Stability and Handling?
Co-lyophilizing three compounds with significantly different molecular weights (403.93 Da, 1,419.5 Da, 4,963 Da) in a single vial requires quality verification across all three simultaneously.
Storage and Reconstitution
Lyophilized GLOW Blend is stable at −20°C for up to 24 months when protected from moisture and light. All three components co-lyophilize as a single powder and reconstitute as a single solution with bacteriostatic water; no separate reconstitution or mixing is required. Once reconstituted, solutions should be held at 2–8°C and used within 14 days. The copper content of GHK-Cu is stable under standard peptide storage conditions; avoid strongly reducing reconstitution buffers, which can affect copper coordination.
Tri-Compound COA Verification
GLOW Blend COA verification requires independent confirmation of all three components in each lot. HPLC purity (≥98% per component) combined with mass spectrometry at three molecular weight targets (403.93 Da for GHK-Cu, 1,419.5 Da for BPC-157, 4,963 Da for TB-500) is the minimum quality standard. TB-500’s large MW (4,963 Da) makes MS verification particularly important, as partial synthesis sequences cannot be excluded by HPLC purity alone. Copper content confirmation for the GHK-Cu component should be included in the COA. All YPB GLOW Blend batches include lot-traceable COA documentation covering all three components, accessible through the COA Library.
Key Research Findings: GLOW Blend in 2026
Key Research Findings
- Three fully non-overlapping mechanisms: GHK-Cu (gene expression, 4,000+ genes), BPC-157 (VEGFR2/NO, angiogenesis), TB-500 (G-actin/LKKTETQ, cell migration) — no shared receptor, signaling cascade, or downstream effector across all three.
- 1,600+ combined publications: GHK-Cu (300+) + BPC-157 (800+) + TB-500 (400+) — the deepest combined evidence base of any three-compound research blend in the YPB catalog.
- No published RCT for GLOW Blend co-formulation as of April 2026. Combination rationale is mechanistic; researchers should document this in protocol design.
- GHK-Cu 4,000+ gene modulation: Pickart et al. (2018, PMID: 30011848) genome-wide profiling established GHK-Cu as the broadest gene expression modulator of any compound in the catalog — this layer is absent from the Wolverine Blend.
- TB-500 has the most advanced clinical pipeline: Phase 3 RGN-259 data (60% NK corneal healing vs. 12.5% placebo), Orphan compound 2013, 1,700+ human subjects with no serious adverse events.
- BPC-157 provides the local vascular infrastructure: VEGFR2-mediated angiogenesis at the target tissue site; systematic review confirmed multi-tissue acceleration (Gwyer 2019, PMID: 31309676).
- Tri-compound COA verification required: MS confirmation at 403.93 Da (GHK-Cu + copper), 1,419.5 Da (BPC-157), and 4,963 Da (TB-500) in each lot — the most comprehensive quality verification requirement of any YPB blend.
- Natural upgrade from Wolverine Blend: Adding GHK-Cu’s gene expression layer to BPC-157 + TB-500 creates a three-mechanism protocol that directly extends two-compound Wolverine Blend research while adding the genomic dimension.
Browse the Full Research Catalog
Why Is the GLOW Blend a High-Demand Research Formulation?
The GLOW Blend draws directly from the search demand of its three component compounds. BPC-157 (165,000/mo), TB-500 (74,000/mo), and GHK-Cu (90,500/mo) are three of the five highest-volume research peptide searches in the YPB catalog. Any buyer searching for all three is a natural GLOW Blend prospect, and the blend captures co-search traffic from all three audiences simultaneously.
Market Demand Indicators
| Demand Indicator | GLOW Blend Data Point |
|---|---|
| BPC-157 monthly searches | 165,000/mo (component compound) |
| GHK-Cu monthly searches | 90,500/mo (component compound) |
| TB-500 monthly searches | 74,000/mo (component compound) |
| Combined component publications | 1,600+ (GHK-Cu: 300+ / BPC-157: 800+ / TB-500: 400+) |
| Clinical stage (components) | BPC-157: Phase 2 (GI); TB-500: Phase 3 (ophthalmic), Orphan compound; GHK-Cu: cosmeceutical |
| Natural upgrade source | Wolverine Blend buyers adding GHK-Cu’s gene expression layer to existing two-compound protocols |
| Keyword difficulty range | Low-medium (KD <15 for GLOW blend-specific terms) |
| Research narrative | Three non-overlapping mechanisms; 1,600+ publications; highest combined evidence base in YPB healing catalog |
How Can Researchers Offer the GLOW Blend Under Their Own Brand?
YourPeptideBrand.com provides white-label dropship for the GLOW Blend in a single configuration. As the highest-mechanism-count healing blend in the catalog, it commands the highest per-unit margin of any YPB blend product and the highest upsell potential from Wolverine Blend buyers.
GLOW Blend Wholesale Pricing & Margin Analysis
| SKU | Configuration | Premier ($497/mo) | Core ($297/mo) | Suggested MSRP | Premier Margin |
|---|---|---|---|---|---|
| YPB.218 (RUO) | GLOW Blend (GHK-Cu ~45mg + BPC-157 10mg + TB-500 10mg) | $81.96 | $98.35 | $165.00 | $83.04 (50%) |
Use the YPB Profit Calculator to model projected monthly revenue. At $83.04 per unit, the GLOW Blend generates more gross margin per transaction than the Wolverine Blend 10mg ($101.49) on an absolute basis when accounting for the $165 MSRP at Premier tier. White-label brands offering the full healing blend progression — Wolverine Blend → GLOW Blend → GLOW Blend + standalone GHK-Cu for advanced protocols — capture all three healing research buyer segments from a single category content investment. Download the full catalog for complete healing category pricing.
Methodology & Data Sources
Methodology & Data Sources
Scientific literature: PubMed searched for GHK-Cu (CAS 49557-75-7), BPC-157 (CAS 137525-51-0), and TB-500 (CAS 77591-33-4) individually; combination search terms “GHK-Cu BPC-157 TB-500 combination” returned no published RCT for the co-formulated blend. Search conducted through April 2026.
Key sources: Pickart et al. (2018) Int J Mol Sci (GHK-Cu 4,000+ gene modulation, PMID: 30011848); Gwyer et al. (2019) Wound Repair Regen (BPC-157 systematic review, PMID: 31309676); Sosne et al. (2023) Int J Mol Sci (TB-500 Phase 3 SEER-1); Philp et al. (2004) FASEB J (TB-500 wound healing breadth, PMID: 15100427).
Limitations: No published RCT exists for the co-formulated GLOW Blend. Combination rationale is mechanistic. Researchers should document the distinction between blend-specific and component-specific evidence in protocol design. This article is for educational purposes and does not constitute medical or research protocol advice.
References
- Pickart, L., Vasquez-Soltero, J. M., & Margolina, A. (2018). GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Int J Mol Sci, 19(7), 1987. PMID: 30011848
- Pickart, L., & Margolina, A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci, 19(7), 1987. PMID: 30011848
- Gwyer, D., Wragg, N. M., & Wilson, S. L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Wound Repair Regen, 27(2), 153–162. PMID: 31309676
- Chang, C. H., Tsai, W. C., Lin, M. S., Hsu, Y. H., & Pang, J. H. (2014). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol, 110(3), 774–780. PMID: 24786597
- Philp, D., Badamchian, M., Scheremeta, B., et al. (2004). Thymosin β4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice. FASEB J, 18(3), 393–397. PMID: 15100427
- Sosne, G., Ousler, G. W., Meenan, R., et al. (2023). 0.1% RGN-259 (Thymosin β4) ophthalmic solution promotes healing in neurotrophic keratopathy research subjects in a Phase III clinical trial. Int J Mol Sci, 24(1), 554. DOI: 10.3390/ijms24010554
- Pickart, L., & Thaler, M. M. (1973). Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature New Biol, 243, 85–87. (GHK-Cu first isolation from human plasma.)
- Sikirić, P., Seiwerth, S., Rucman, R., et al. (2013). Stable gastric pentadecapeptide BPC 157 — novel therapy in gastrointestinal tract. Curr Pharm Des, 17, 1612–1632. PMID: 21548867
- Goldstein, A. L., & Hannappel, E. (2005). Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med, 11(9), 421–429. PMID: 16099185
Frequently Asked Questions
The GLOW Blend (YPB.218) is a co-lyophilized research formulation containing GHK-Cu (glycyl-L-histidyl-L-lysine copper(II), CAS: 49557-75-7, ~45mg), BPC-157 (Body Protection Compound, CAS: 137525-51-0, 10mg), and TB-500 (Thymosin Beta-4, CAS: 77591-33-4, 10mg). In published research, each component addresses tissue repair through a distinct, non-overlapping mechanism: GHK-Cu modulates 4,000+ genes at nanomolar concentrations via an epigenetic/transcriptional mechanism (Pickart et al. 2018, PMID: 30011848); BPC-157 activates VEGFR2/NO angiogenesis locally (Gwyer et al. 2019, PMID: 31309676); TB-500 sequesters G-actin to enhance systemic cell migration (Philp et al. 2004, PMID: 15100427). No published RCT for the co-formulated blend exists as of April 2026. All products are Research Use Only (RUO).
As of April 2026, no published randomized controlled trial exists evaluating the co-formulated GHK-Cu + BPC-157 + TB-500 blend as a single intervention. The combination rationale is mechanistic: the three compounds address different cellular requirements of tissue repair without shared receptor targets, and their mechanisms address three distinct biological scales (gene expression, vascularization, cell migration). The combined evidence base of 1,600+ publications (GHK-Cu: 300+, BPC-157: 800+, TB-500: 400+) provides extensive support for each component independently. Researchers designing protocols using the GLOW Blend should document the mechanistic rationale while noting that blend-specific RCT data is not available. Individual compound evidence is covered in the GHK-Cu, BPC-157, and TB-500 research guides.
The Wolverine Blend (BPC-157 + TB-500) provides two non-overlapping mechanisms: local VEGFR2/NO vascularization (BPC-157) and systemic G-actin-mediated cell migration (TB-500). The GLOW Blend adds GHK-Cu as a third, fully non-overlapping mechanism operating at the gene expression level — modulating 4,000+ genes associated with tissue repair, ECM remodeling, collagen synthesis, and the gene expression environment characteristic of younger tissue. GHK-Cu’s mechanism does not overlap with either BPC-157 (no VEGFR2 activity) or TB-500 (no actin binding). For researchers studying tissue repair at the mechanistic level, the choice between the two blends depends on whether the protocol requires the gene expression layer that only GHK-Cu provides. Neither blend has a published RCT as a co-formulated single intervention.
GLOW Blend quality verification requires independent confirmation of all three components in each lot. HPLC purity (≥98% per component) and mass spectrometry at three molecular weight targets is required: 403.93 Da (GHK-Cu, with copper coordination confirmation), 1,419.5 Da (BPC-157), and 4,963 Da (TB-500). TB-500’s 4,963 Da molecular weight makes MS verification particularly critical, as partial sequence synthesis cannot be excluded by HPLC purity alone. Copper content verification for the GHK-Cu component is included in the YPB COA protocol. Endotoxin (<1 EU/mg combined), TAMC, and TYMC are also included. All lots are traceable through the COA Library.
No published human safety data exists for the co-formulated GLOW Blend. For TB-500, the RGN-259 program (1,700+ subjects across SEER-1, SEER-2, SEER-3, and Phase 2 dry eye trials) reported no serious compound-related adverse events at any studied dose (Sosne et al. 2023). For BPC-157, Phase 2 IBD trial (NCT03000296) preliminary disclosures indicate well-tolerated profile with no serious adverse events. For GHK-Cu, published cosmeceutical and topical data documents excellent tolerability; injectable human data is limited. Each compound’s safety data is specific to that compound and cannot be directly attributed to the combination. All YPB GLOW Blend products are Research Use Only.
Yes. YourPeptideBrand.com provides white-label dropship for the GLOW Blend at $81.96 Premier wholesale, with a suggested MSRP of $165 generating $83.04 gross margin per unit (50% margin). White-label storefronts include pre-built RUO-compliant product pages with tri-compound molecular data tables, mechanism descriptions, and COA library links covering all three components. Operators set retail pricing and keep the margin; YPB handles all fulfillment. Storefronts launch within 30 days with no inventory requirements. Use the profit calculator to model projected revenue at your MSRP.
The GLOW Blend is best positioned as the natural protocol upgrade for researchers who have studied the Wolverine Blend (BPC-157 + TB-500) and want to extend their research to include the gene expression layer that GHK-Cu provides. The positioning is additive, not competitive: a buyer researching Wolverine Blend is the ideal GLOW Blend candidate. White-label brands offering both products capture the same healing research buyer at two price points ($100–$180 for Wolverine, $165 for GLOW), with the GLOW Blend commanding a premium for the additional mechanism. Brands with GHK-Cu standalone content can cross-link directly to the GLOW Blend as the three-compound application of GHK-Cu’s gene expression research alongside the most-studied healing peptide pair in the category.
Premier tier members ($497/mo) access GLOW Blend at $81.96 wholesale, generating $83.04 gross margin per unit at the suggested $165 MSRP (50% margin). Core tier ($297/mo) pricing is $98.35. The GLOW Blend is the highest-MSRP healing blend in the YPB catalog, and its three-mechanism narrative supports premium positioning over the Wolverine Blend for buyers seeking the most comprehensive healing research tool. White-label brands offering the Wolverine Blend ($78.51 wholesale, $101.49 margin at 10mg) and GLOW Blend together present buyers with a clear mechanism-based upgrade path, capturing both the two-compound and three-compound healing research market from a single healing category audience.
Key Takeaways
Research Takeaways
- Three fully non-overlapping mechanisms: Gene expression (GHK-Cu: 4,000+ genes), vascularization (BPC-157: VEGFR2/NO), cell migration (TB-500: G-actin/LKKTETQ) — the most mechanistically comprehensive healing research blend in the YPB catalog.
- 1,600+ combined publications across all three components — the deepest evidence base of any three-compound blend, with each component independently characterized across multiple independent research groups.
- No published RCT for the co-formulated GLOW Blend as of April 2026 — combination rationale is mechanistic; researchers should document this distinction in protocol design.
- GHK-Cu adds the gene expression layer absent from the Wolverine Blend: 4,000+ gene modulation at nanomolar concentrations (Pickart et al. 2018, PMID: 30011848) creates the transcriptional environment for tissue repair that BPC-157 and TB-500 alone cannot address.
- TB-500 has the most advanced clinical pipeline (Phase 3, Orphan compound, 1,700+ human subjects, no serious adverse events); BPC-157 in Phase 2 GI trial; GHK-Cu has extensive cosmeceutical topical data.
- Tri-compound COA required — MS confirmation at three molecular weights (403.93 Da, 1,419.5 Da, 4,963 Da) with copper content verification; most rigorous quality documentation of any YPB blend.
- Natural upgrade from Wolverine Blend for researchers extending two-mechanism to three-mechanism protocols.
Business Takeaways
- $83.04 gross margin per unit at Premier tier (50%) — highest-MSRP healing blend at $165; three-mechanism narrative supports premium positioning.
- Captures co-search traffic from BPC-157 (165K/mo), GHK-Cu (90.5K/mo), and TB-500 (74K/mo) — three of the five highest-volume research peptide searches simultaneously.
- Wolverine Blend → GLOW Blend is the highest-value upsell in the healing category — same buyer, natural protocol evolution, $22 higher margin per transaction at Premier tier.
- Complete healing blend ladder: BPC-157 standalone → TB-500 standalone → Wolverine Blend → GLOW Blend — four progressively comprehensive products from one buyer segment.
Ready to add the GLOW Blend to your research peptide catalog? Book a consultation with the YPB team.
[ypb_studies peptide=”ghk-cu bpc-157 tb-500″]